 "Nearly half of US physicians open to prescribe more biosimilars: Survey")
Efficacy and safety considerations notwithstanding, US physician are poised to embrace biosimilars as a potentially important way to reduce patient drug costs, according to a new MicroSyndicated survey from InCrowd, which provides real time market research report about physician to companies worldwide. In the survey targeted US biologics prescribers shared their perceptions regarding the onset of biosimilars - lower cost, similar yet not identical versions of already FDA-approved biologic drugs.
Nearly half of US doctors in five major specialty areas surveyed - physicians with significant biologics prescribing patterns - anticipate expanding their prescribing of biosimilars in the next three years, as biosimilar availability increases. Respondents ranked lower costs for patients as the chief way biosimilars could bring value to their patients. Reflecting practical considerations, one in four doctors said that payers and insurance firms ultimately will determine - if not mandate - their level of biosimilar prescribing over the next three years.
“If they are equally effective, and cheaper, it’s tough to see a downside,” said one dermatologist in the survey.
About 17 percent of respondents felt biosimilars would become the norm or replace biologics in the next three years. Questions concerning pharmacy-level substitutions offered mixed results with only two out of 10 stated they were likely to strictly prohibit pharmacy-level substitution of the originator biologic with biosimilars.
As per the survey, efficacy (89 percent) and safety (81 percent) outranked patient costs (71 percent) among the top important factors in determining whether health care professionals would prescribe biosimilars.
Nearly half of US doctors in five major specialty areas surveyed - physicians with significant biologics prescribing patterns - anticipate expanding their prescribing of biosimilars in the next three years, as biosimilar availability increases. Respondents ranked lower costs for patients as the chief way biosimilars could bring value to their patients. Reflecting practical considerations, one in four doctors said that payers and insurance firms ultimately will determine - if not mandate - their level of biosimilar prescribing over the next three years.
“If they are equally effective, and cheaper, it’s tough to see a downside,” said one dermatologist in the survey.
About 17 percent of respondents felt biosimilars would become the norm or replace biologics in the next three years. Questions concerning pharmacy-level substitutions offered mixed results with only two out of 10 stated they were likely to strictly prohibit pharmacy-level substitution of the originator biologic with biosimilars.
As per the survey, efficacy (89 percent) and safety (81 percent) outranked patient costs (71 percent) among the top important factors in determining whether health care professionals would prescribe biosimilars.
Discounts drove anticipated prescribing patterns. Assuming physicians had the choice between an FDA approved biosimilar and its originator biologic, 83 percent would prescribe a biosimilar if it were 25 percent cheaper - versus just 33 percent if it were 5% cheaper, added the InCrowd survey.
Physicians expect to prescribe biosimilars to a greater proportion of their treatment-naive patients (49 percent) - those who have never tried any drug treatment - than to patients currently or previously treated with the originator biologics (30 percent and 38 percent, respectively).
“As the healthcare industry grapples with the best strategies to lower drug costs, the MicroSyndicated survey shows that while understandably prioritizing efficacy and safety first, physicians are on board with their use. The key will lie in how payers decide to reimburse for biosimilars and their biologic counterparts,” said Diane Hayes, president and co-founder of InCrowd.
Physicians expect to prescribe biosimilars to a greater proportion of their treatment-naive patients (49 percent) - those who have never tried any drug treatment - than to patients currently or previously treated with the originator biologics (30 percent and 38 percent, respectively).
“As the healthcare industry grapples with the best strategies to lower drug costs, the MicroSyndicated survey shows that while understandably prioritizing efficacy and safety first, physicians are on board with their use. The key will lie in how payers decide to reimburse for biosimilars and their biologic counterparts,” said Diane Hayes, president and co-founder of InCrowd.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%